CyFlow NK1.1 Low Endotoxin
品番 | BL131384 | ||
---|---|---|---|
抗体名 | Anti-Ms NK1.1 LOW END,PK136 | ||
包装単位 | 0.1 mg | ||
濃度 | 1 mg/ml | ||
容量 | 0.1 ml | ||
関連製品 (アイソタイプコントロール) |
- | ||
反応性|交差吸着 | Mouse | レーザー | |
抗原 | NK1.1, CD161bc | 最大蛍光波長 | - |
クローン | PK136 | 最大励起波長 | - |
ホスト | Mouse | 標識/Format | Low Endotoxin |
アイソタイプ | IgG2a | 研究分野 | Immunophenotyping | MHC |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Ms NK1.1 LOW END,PK136
特異性
The mouse monoclonal antibody PK136 recognizes NK1.1 (CD161bc) antigen (NK cell marker) expressed by some mouse strains (e.g. C57BL/6, NZB, CE, C58, Ma/My), whereas other strains (e.g. BALB/c, AKR, CBA, C3H) do not express this antigen. This antibody detects a conformational epitope on Nkrp1c and Nkrp1b gene products.
抗原情報
NK1.1 (CD161bc and also known as NKRP1, Ly55c, or Ly59) is a cell surface antigen expressed on NK cells and NK-T cells of certain mouse strains, which is being used for identification or antibody-mediated depletion of these cells in the respective strains. This antigen participates in NK cell activation, including production of interferon gamma, and release of cytotoxic granules.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Carlyle JR, Mesci A, Ljutic B, Belanger S, Tai LH, Rousselle E, Troke AD, Proteau MF, Makrigiannis AP: Molecular and genetic basis for strain‑dependent NK1.1 alloreactivity of mouse NK cells. J·Immunol. 2006·Jun·15; 176(12):7511‑24. <·PMID:·16751398·>
• Carroll JL, Nielsen LL, Pruett SB, Mathis JM: The role of natural killer cells in adenovirus‑mediated p53 gene therapy. Mol·Cancer·Ther. 2001·Nov; 1(1):49‑60. <·PMID:·12467238·>
• Fang M, Lanier LL, Sigal LJ: A role for NKG2D in NK cell‑mediated resistance to poxvirus disease. PLoS·Pathog. 2008·Feb·8; 4(2):e30. <·PMID:·18266471·>
• GeurtsvanKessel CH, Bergen IM, Muskens F, Boon L, Hoogsteden HC, Osterhaus AD, Rimmelzwaan GF, Lambrecht BN: Both conventional and interferon killer dendritic cells have antigen‑presenting capacity during influenza virus infection. PLoS·One. 2009·Sep·28; 4(9):e7187. <·PMID:·19784375·>
• Joncker NT, Shifrin N, Delebecque F, Raulet DH: Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. J·Exp·Med. 2010·Sep·27; 207(10):2065‑72. <·PMID:·20819928·>
• Kulesza J, Hoser G, Wasilewska D, Kawiak J: NK cell depletion and recovery in SCID mice treated with anti‑NK1.1 antibody. Folia·Histochem·Cytobiol. 2006; 44(2):93‑6. <·PMID:·16805133·>
• Laffont S, Seillet C, Ortaldo J, Coudert JD, Guéry JC: Natural killer cells recruited into lymph nodes inhibit alloreactive T‑cell activation through perforin‑mediated killing of donor allogeneic dendritic cells. Blood. 2008·Aug·1; 112(3):661‑71. <·PMID:·18505782·>
• Símová J, Bubeník J, Bieblová J, Jandlová T: The role of NK1.1+ cells in the protection against MHC class I+ HPV16‑associated tumours. Folia·Biol·(Praha). 2004; 50(6):200‑2. <·PMID:·15709715·>
• Takahashi S, Kawamura T, Kanda Y, Taniguchi T, Nishizawa T, Iiai T, Hatakeyama K, Abo T: Activation of CD1d‑independent NK1.1+ T cells in the large intestine by Lactobacilli. Immunol·Lett. 2006·Jan·15; 102(1):74‑8. <·PMID:·16107279·>
• Wang M, Ellison CA, Gartner JG, HayGlass KT: Natural killer cell depletion fails to influence initial CD4 T cell commitment in vivo in exogenous antigen‑stimulated cytokine and antibody responses. J·Immunol. 1998·Feb·1; 160(3):1098‑105. <·PMID:·9570522·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN